Dr. Mayank Singhal is an Associate Principal Scientist in Early Product Development and Manufacturing, AstraZeneca, UK. Mayank has experience in clinical drug product development following a risk-based approach using predictive modelling tools and characterization techniques to expedite the drug product development. Mayank received his PhD from the University of Geneva and pursued his Postdoc at the University of Helsinki on nanoparticles funded by the Swiss National Science Foundation. Mayank is passionate about advancing science through collaboration and develop strategy around delivery of clinical formulations of challenging brick dust compounds.